Dr. Sanjay Gupta is a Professor & Research Director and holds Carter Kissell Endowed Chair in Urologic Oncology in the Department of Urology at Case Western Reserve University and The Urology Institute at the University Hospitals Cleveland Medical Center. He also holds secondary appointments in the Departments of Nutrition and Division of General Medical Sciences at Case Comprehensive Cancer Center. Dr. Gupta has joint appointment as Research Scientist at the Louis Stokes VA Medical Center, Cleveland, Ohio. Dr. Gupta obtained faculty position in 2002 at Case Western Reserve University, School of Medicine. Dr. Gupta’s research involves basic, translational and clinical areas of focus. In basic research his focus is to understand the risk factors and mechanisms of prostatic, breast, kidney and bladder diseases and develop appropriate biomarkers for early detection and prognosis. Translational research focus is to identify novel targets to monitor the efficacy of various synthetic and natural small molecules and develop them as chemo preventatives/therapeutics. His clinical research interests are translation of bench research to its application in clinics. Dr. Gupta has authored some 150 publications, including book chapters, research articles and reviews, and has spoken at several occasions in cancer prevention symposium, seminars and meetings both nationally and internationally. He has been serving in various study sections at National Cancer Institute (NCI) and Department of Defense (DOD), and other councils around the globe. He also serves on the Editorial board as well as reviewer for several prestigious scientific journals. His innovative research on basic and translational aspects has been featured on NBC-5 news and highlighted in the Plain Dealer, and American Association for Cancer Research, and American Urological Association press release.
Prof. Dr. Sanjay Gupta Research interests are • Molecular mechanism(s) of prostate and bladder carcinogenesis • Role of inflammation in promoting prostate and bladder cancer • Biomarker(s) for detection and prognosis of GU malignancies • Identification and characterization of prostate cancer stem cells • Epigenetic mechanisms of gene silencing in prostate/bladder cancer and its reversal by natural agents • Molecular targets for prevention and treatment of prostate cancer • Chemoprevention of prostate/bladder cancer by naturally occurring and/or synthetic compounds • Drug repurposing, mechanism(s) of action with non-chemotherapeutic agents • Clinical trials with promising agents and their combinations • Nano-pharmaceutical formulations for targeted drug delivery